Smoore International Releases Strong First Half-Year Performance Report

Market by 2FIRSTS.ai
Aug.21.2023
Smoore International Releases Strong First Half-Year Performance Report
Smoore International (06969.HK) reports 9.4% decline in H1 2023 revenue of RMB 5.123 billion but steady net profit of RMB 758 million.

On August 21, Smoore International (06969.HK) released its performance report for the first half of 2023. According to the financial report, Sinopec's operating revenue for the first half of 2023 was RMB 5.123 billion, which represents a 9.4% decrease compared to the previous year. However, the adjusted net profit was RMB 758 million, demonstrating the company's solid operational strength. The revenue from overseas markets was RMB 5.061 billion, showing a 28% year-on-year growth and indicating promising growth prospects.

 

Mr. Chen Zhiping, Executive Director, Chairman of the Board, and Chief Executive Officer of Smoore, said, "In the first half of 2023, our operations were temporarily impacted by rapidly changing market conditions and external factors, resulting in a certain degree of decline in revenue and profits. However, during this period, we have consistently improved management efficiency, built marketing capabilities, and strengthened research and development capabilities. Therefore, we remain optimistic about the future operations of the company and have confidence in the bright prospects of the atomization business.

 

More than 90% of the company's revenue comes from overseas, with disposable income increasing threefold year-on-year. Simoer is actively expanding its presence in the electronic vaporizer market to achieve a diversified revenue distribution. The revenue from enterprise customer business (ODM) reached 4.474 billion yuan, accounting for 87.3% of the total revenue. The revenue from overseas markets has steadily increased, with a year-on-year growth of 30%. Among them, the group has achieved further breakthroughs in the US market by enhancing production intelligence level and optimizing cost structure, with a revenue share of 40.2% and a year-on-year growth of 27.7%.

 

In addition, Smoore has experienced rapid growth in Europe and other markets, with a YoY increase of 32%. Particularly, their disposable products have seen a massive surge in shipments, with revenues increasing by 369% compared to the previous year. Thanks to their high technological barriers, the company has successfully launched the FEELM Max, a ceramic-core disposable atomization solution, which boasts a "30% or more boost in puffs, ultimate purity and smoothness, and consistent performance for every puff." Additionally, they have also introduced TOPOWER, a globally leading battery technology that offers consumers a non-rechargeable, long-lasting usage experience.

 

In addition, the group achieved further growth in its retail customer (APV) business, benefiting from a dual boost of product upgrades and channel expansion. In the first half of 2023, the revenue reached RMB 649 million, representing a year-on-year growth of 15.8%.

 

Semoer, the company, has actively expanded its research and development (R&D) efforts and made significant investments in four major fogging tracks, with R&D spending reaching a remarkable 615 million yuan, representing a year-on-year increase of 1.8%. Moreover, the proportion of R&D expenditure in total revenue has risen to 12%. In addition to this, the company has also made strong efforts to enhance the protection of its intellectual property, resulting in a substantial increase in patent applications, totaling 1,154.

 

In terms of enterprise clients (ODM), Smoore has comprehensively upgraded the global first ceramic-core disposable solution, FEELM Max, providing direction for the next stage of industry development. With the standardized 800 puff count, FEELM has redefined industry standards for 2ml cartridges. At the same time, it has achieved a breakthrough in high-capacity cartridges, as FEELM's TOPOWER technology solves the problem of battery life, allowing high-capacity products to truly be "disposable, no charging required.

 

In the retail customer (APV) business, the group has released iterative products LUXE XR MAX and XROS 3 NANO, building upon the success of their previous bestsellers LUXE X and XROS series, which have further increased the group's market share in the open-ended product market. Additionally, the group's newly launched products, VAPORESSO COSS and VAPORESSO ECO NANO, feature functions such as automatic liquid injection, automatic charging, and exceptional battery life, further enhancing the group's overall strength.

 

Simore has successfully managed to navigate the rapidly changing market and external challenges, thanks to their professional expertise in product research and development, marketing, and compliance management. They have consistently delivered value to both clients and consumers.

 

Additionally, the group will continue to expand its presence in four major sectors: electronic vaporization, heated non-combustible products, specialized vaporization products, and medical vaporization. The objective is to establish a leading global platform for vaporization technology.

 

Meanwhile, the market in the field of electronic atomization still has significant potential for growth. The industry is still in the development stage of low market penetration, fast product iteration, and continuous expansion of market space. Simoer will gradually launch more innovative disposable products with differentiated advantages in overseas markets to drive revenue growth.

 

In the field of specialized nebulized products, the group plans to develop and launch more innovative products systematically, in order to enhance its competitiveness in this area. Simultaneously, the group is dedicated to changing the drug administration methods in the field of nebulized medicine, aiming to provide more precise, efficient, and cost-effective nebulized drug delivery solutions for patients with respiratory system disorders. Additionally, the group's research and development in the field of nebulized medicine is progressing steadily, with plans to continue conducting research on various pharmaceutical development projects in the second half of the year, as per schedule.

 

The company will also continue its mission of "enhancing life through atomization" and focus on building a globally leading atomization technology platform. With a strategic focus on "leading technology manufacturing, diversified core technologies, and branded technological innovations," the company will continuously improve its technological capabilities and expand its application areas.

 

Source: Smoore

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
mperial Brands’ HY26 results point to a more selective NGP transition. The company is using cash flow from traditional tobacco to fund targeted investments in modern oral nicotine, heated tobacco and reusable vaping systems. Its decision to exit the legacy myblu vaping business in the U.S., while expanding Zone nicotine pouches. In Europe, Imperial’s NGP growth is being driven by a multi-category portfolio including blu, Pulze and Zone/Skruf.
Special Report
May.12
AIR Shares Drop 18.6% in Nasdaq Debut, Testing Hookah’s Move Toward Public Markets
AIR Shares Drop 18.6% in Nasdaq Debut, Testing Hookah’s Move Toward Public Markets
AIR Global’s Nasdaq debut under ticker AIIR ended with a 18.6% first-day decline, giving the global hookah industry a rare public-market reference point. Beyond one company’s share move, the listing raises a broader question: can a culturally rooted, fragmented and venue-based category evolve into a more scalable and investable consumer sector?
Special Report
May.19
Multi-State Coalition Urges F1 to End Nicotine Sponsorships, Citing Zyn and Velo
Multi-State Coalition Urges F1 to End Nicotine Sponsorships, Citing Zyn and Velo
Hawaii Attorney General Anne Lopez is co-leading a coalition of 19 states and jurisdictions urging the Fédération Internationale de l’Automobile (FIA) and Formula 1 to end sponsorships involving tobacco and nicotine products, including nicotine pouch brands such as Zyn and Velo.
News
Jun.09
Bloomberg: Zyn’s Dry-Mouth Problem Threatens Its Hold on Nicotine Pouch Market
Bloomberg: Zyn’s Dry-Mouth Problem Threatens Its Hold on Nicotine Pouch Market
According to Bloomberg, Philip Morris International’s Zyn is facing growing competition in the U.S. nicotine pouch market as consumers shift toward moister alternatives such as British American Tobacco’s Velo Plus.
BATPMI
May.22
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Haypp Group reported a 40% year-on-year increase in nicotine pouch volumes in the first quarter of 2026, with U.S. and U.K. volumes rising 123% and 102%, respectively. Haypp says around 97% of its consumer traffic is organic and that its Media & Insights business provides brand owners with on-site visibility, trial activation and consumer intelligence. For international tobacco companies, Haypp may be both a growth partner for modern oral products and a new source of channel leverage.
Special Report
May.22